News

Dendy Engelman, MD, FACMS, FAAD, explores the latest advancements in laser and energy-based dermatological treatments, including skin resurfacing and body contouring.

Kolansky identifies oxybenzone and fragrances as leading causes of sunscreen allergies.

Whitney Hovenic, MD's new SPOOGE sunscreen hopes to engage Gen Z in sun protection, merging skincare with fun and effective sun care strategies.

The Japanese study found no association between cutaneous events and baseline EASI scores, eosinophil counts, or IgE levels.

Michael Somenek, MD, shares how a first-of-its-kind Galderma trial using Sculptra and Restylane helped restore volume and skin quality in patients on GLP-1 medications.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of August.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Deucravacitinib-treated patients achieved superior clinical responses compared to placebo at week 16 in both trials.

In a discussion on pediatric AD management, Shanna Miranti, MPAS, PA-C, emphasized the enduring role of topical treatments for residual itch and flares, and highlighted the importance of rapid-acting agents such as ruxolitinib cream.

Discover how the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai leads in innovative skin cancer care and research, celebrating a decade of excellence.

Renata Block, DMSc, MMS, PA-C, interviews Adam Friedman, MD, FAAD, about his research into cannabidiol’s photoprotective potential, clinical trial design, and future directions.

Whitney Hovenic, MD, highlights alarming trends in Gen Z's sun protection habits and introduces SPOOGE, a new sunscreen brand promoting skin health.

O'Dowd discusses J&J's recent NDA submission for icotrokinra in psoriasis.

The open-label trial showed dusquetide produced similar results to apremilast in reducing oral ulcers, pain, and ulcer duration.

At a recent Dermatology Times Case-Based Roundtable, attendees discussed several challenging AD cases.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Deepti Gupta, MD, emphasized SPD's focus on delivering practical clinical insights, highlighting emerging research, and fostering meaningful professional connections

Explore career transitions in healthcare as PAs Renata Block, DMS-c, MMS, PA-C, and Jessica Dell'Aquila, MS, PA-C, share insights on professional growth and evolving roles in dermatology.

PC111, a novel therapy from Scinai, targets pemphigus vulgaris and SJS/TEN, offering rapid relief without immunosuppression.

VYNE Therapeutics reveals disappointing phase 2b trial results for repibresib gel in nonsegmental vitiligo, missing key efficacy endpoints.

AbbVie's upadacitinib showed promising results in treating severe alopecia areata, achieving significant hair regrowth in pivotal phase 3 trials.

Delgocitinib cream recently became the first FDA-approved treatment for chronic hand eczema. Robert Spurr of LEO Pharma shares insights into what it means for providers and patients.

This review of the latest dermatologic studies includes insights into emerging terbinafine resistant trichophyton dermatophytosis, clinicodemographic features and usage of oral immunosuppressive agents in childhood and adolescent vitiligo, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Coates addresses social determinants of health in pediatric dermatology, emphasizing their impact on treatment and patient outcomes.

Lauren Madigan, MD, shares vital insights on complex dermatology, emphasizing accurate diagnoses and the importance of diversity in dermatologic imagery.

At Elevate-Derm Summer, Buchi Neita, MCMSc, PA-C, discussed enhancing dermatologic care for patients with skin of color by recognizing characteristics in common conditions and offered strategies to build rapport with patients.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Nektar Therapeutics advances alopecia areata treatment with FDA's Fast Track designation for rezpegaldesleukin, targeting immune modulation in chronic hair loss.

Johnson & Johnson seeks FDA approval to update guselkumab's label, highlighting its unique ability to significantly inhibit joint damage in active psoriatic arthritis.